REG - Thruvision Group PLC - Director/PDMR Shareholding

ThruvisionAnnouncement

Mon 11:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250929:nRSc2230Ba&default-theme=true

RNS Number : 2230B  Thruvision Group PLC  29 September 2025

29 September 2025

 

Thruvision Group plc

 

("Thruvision" or the "Company")

 

Director Share Dealing

 

Thruvision (AIM: THRU, "Thruvision" or the "Group"), the leading international
provider of walk- through security technology, announces that on 26 September
2025 Mark Nurse, the husband and accordingly a person closely associated
("PCA") with Katrina Nurse, sold 10,000 ordinary shares in the Company at a
price of 1.23 pence.

 

Following this transaction, the beneficial shareholding in the Company of
Katrina Nurse and her PCAs is 258,000 ordinary shares, representing 0.06% of
the Company's total issued share capital and total voting rights.

 

The notification below, made in accordance with the requirements of the Market
Abuse Regulation, provides further detail:

 

 1.   Details of the person discharging managerial responsibilities/person closely
      associated
 (a)  Name                                             Mark Nurse, husband of Katrina Nurse
 2.   Reason for the notification
 (a)  Position/status                                  Person closely associated with Katrina Nurse, a Non-Executive Director
 (b)  Initial notification/ Amendment                  Initial notification
 3.   Details of the issuer
 (a)  Name                                             Thruvision Group plc
 (b)  LEI                                              213800IZG9GM6G2TZE04
 4.   Details of the transaction(s): section to be repeated for (i) each type of
      instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted
 (a)  Description of the Financial Instrument          Ordinary shares of £0.01 each
 (b)  Identification code of the Financial Instrument  GB00B627R876
 (c)  Nature of the transaction                        Sale of shares

 (d)  Price(s) and volume(s)                           Price(s)                              Volume(s)
                                                       1.23 pence                            10,000

 (e)  Aggregated information                           N/A

      -              Aggregated volume

      -              Price
 (f)  Date of the transaction                          26 September 2025
 (g)  Place of the transaction                         London Stock Exchange

 

For further information please contact:

 

 Thruvision Group                                                              +44 (0)1235 425 400
 plc

 Tom Black, Executive Chairman

 Victoria Balchin, Chief Executive Officer and Chief Financial Officer

 Allenby (Nominated Adviser & Broker)                                          +44 (0)20 3328 5656

 James Reeve / Piers Shimwell (Corporate Finance)

 Jos Pinnington / Amrit Nahal (Sales)

 

About Thruvision (www.thruvision.com (http://www.thruvision.com/) )

Thruvision is a leading developer, manufacturer and supplier of advanced
AI-based walk- through security technology internationally. Its technology is
deployed in more than 30 countries around the world by government and
commercial organisations in a wide range of security situations, where large
numbers of people need to be screened quickly, safely and efficiently.
Thruvision's patented technology is uniquely capable of detecting concealed
objects in real time using advanced AI-based detection algorithms. The Group's
offices are near Oxford and Washington DC.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHBGGDCUDDDGUC